MAPT and Alzheimer disease: The intensive attempts to develop disease-modifying therapeutics targeting Aβ or tau protein, neuroprotective strategies, and immunotherapies for AD treatment have proceeded; however, there has been no new approved drug for the treatment of AD since 2003 [38].